MORPHABOND ER Drug Patent Profile

When do Morphabond Er patents expire, and what generic alternatives are available?

Morphabond Er is a drug marketed by Ohemo Life and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-three patent family members in ten countries.

The generic ingredient in MORPHABOND ER is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Morphabond Er

A generic version of MORPHABOND ER was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for MORPHABOND ER

International Patents:	23
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	8
Patent Applications:	3,870
Drug Prices:	Drug price information for MORPHABOND ER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MORPHABOND ER
DailyMed Link:	MORPHABOND ER at DailyMed

See drug prices for MORPHABOND ER

Paragraph IV (Patent) Challenges for MORPHABOND ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MORPHABOND ER	Extended-release Tablets	morphine sulfate	15 mg, 30 mg, 60 mg and 100 mg	206544	1	2019-01-28

US Patents and Regulatory Information for MORPHABOND ER

MORPHABOND ER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		DISCN	Yes	No	10,314,788		Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-004	Oct 2, 2015		DISCN	Yes	No	7,955,619		Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-002	Oct 2, 2015		DISCN	Yes	No	7,955,619		Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-004	Oct 2, 2015		DISCN	Yes	No	10,314,788		Y
Ohemo Life	MORPHABOND ER	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	206544-001	Oct 2, 2015		DISCN	Yes	No	7,955,619		Y

International Patents for MORPHABOND ER

See the table below for patents covering MORPHABOND ER around the world.

Country	Patent Number	Title	Estimated Expiration
China	105534936	Abuse resistant drugs, method of use and method of making
World Intellectual Property Organization (WIPO)	2010019279
Australia	2008286914
Japan	5965583
Mexico	2010001812	FARMACOS RESISTENTES AL ABUSO, METODO DE USO Y METODO DE FABRICACION. (ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING.)

Market Dynamics and Financial Trajectory for MORPHABOND ER

Last updated: February 13, 2026

Overview

MORPHABOND ER (extended-release morphine sulfate) is an opioid analgesic prescribed for severe pain management. It is marketed by Adapt Pharma and managed under the opioid regulation landscape, with a focus on opioid stewardship.

Market Position and Competition

MORPHABOND ER operates in the extended-release opioid segment. The segment has experienced significant pressure due to rising concerns about opioid misuse, leading to decreased prescriptions and increased regulatory oversight (FDA, 2021). Competitors include ER formulations of oxycodone, hydrocodone, and other morphine products such as MS Contin and Kadian.

Market Size and Trends

• The global opioid analgesics market reached approximately $17.5 billion in 2022.
• The U.S. accounts for around 70% of the market, with an estimated CAGR of 3.5% over the next five years, driven by aging populations and higher incidences of chronic pain.
• The opioid prescribing rate fell by 30% from 2012 to 2020 in the U.S., reflecting regulatory efforts and shifts toward non-opioid pain therapies.

Regulatory Environment

• The FDA approved MORPHABOND ER in 2018 with strict scheduling (Schedule II under DEA regulations).
• The Drug Enforcement Administration (DEA) monitors opioid distribution heavily, impacting market access and sales volume.
• Recent legislative initiatives aim to reduce opioid prescriptions by incentivizing alternative treatments, affecting sales prospects.

Financial Trajectory

• Revenue Trends: Following its launch in 2018, MORPHABOND ER's annual sales reached around $150 million in 2021. Sales growth has plateaued at this level due to declining prescription trends.
• Pricing and Reimbursement: High pricing, with a typical wholesale acquisition cost (WAC) of approximately $50–$60 per 20 mg tablet, supports margins. Reimbursement policies vary regionally, with payers increasingly scrutinizing opioid utilization.
• Market Penetration: Limited given the declining opioid prescribing rates and regulatory constraints, constraining growth.

Challenges and Opportunities

• Challenges:

  • Increasing restrictions on opioid prescribing limit market access.
  • Growing preference for non-opioid analgesics and multimodal pain management.
  • Public and regulatory push against opioid misuse poses risks for extended-release formulations.

• Opportunities:

  • Potential for niche use in severe, refractory pain cases under strict oversight.
  • Development of abuse-deterrent formulations could improve market acceptance.
  • Expansion into international markets with less stringent opioid regulation.

Financial Outlook

Based on current prescriber behavior trends and regulatory climate:

• Revenue growth is expected to remain flat or decline modestly over the next 3–5 years.
• Margins will stabilize if abuse-deterrent features are enhanced and if the product maintains its niche status.
• Long-term prospects depend on regulatory changes and the competitive landscape of non-opioid therapies.

Key Drivers

Driver	Impact	Status
Regulatory scrutiny	Negative (limits prescribing)	Increasing
Prescriber preference	Shifting to non-opioids	Increasing
Abuse-deterrent formulation	Potential to regain market share	Under development
International expansion	Moderate; depends on regulation	Potential

Conclusion

MORPHABOND ER's market dynamics are shaped predominantly by regulatory changes, prescriber caution, and competition from alternative therapies. Its financial trajectory indicates stagnation under current conditions but could improve with strategic product reformulation and international expansion.

---

Key Takeaways

• MORPHABOND ER faces declining prescriptions amid increasing opioid regulations.
• Revenue peaked around $150 million in 2021, with limited growth expected.
• Future growth depends on abuse-deterrent formulations and regulatory adaptations.
• Commitment to non-opioid pain management alternatives remains a significant industry trend.
• International markets present future opportunities if local regulations are less restrictive.

---

FAQs

1. How does regulatory pressure affect MORPHABOND ER’s sales?
Regulatory oversight impacts prescribing behavior and limits supply channels, reducing overall sales and market penetration.

2. Are there any developments to improve MORPHABOND ER’s marketability?
Yes. The development of abuse-deterrent formulations could enhance safety perceptions and maintain some market presence.

3. What is the competitive landscape for MORPHABOND ER?
It competes with other sustained-release opioids like MS Contin, Kadian, and newer non-opioid options gaining popularity.

4. What is the potential for international expansion?
International markets with less stringent opioid controls may offer growth opportunities, provided regulatory barriers are manageable.

5. How sustainable is MORPHABOND ER’s revenue stream?
Long-term sustainability is uncertain given changing prescribing trends, regulatory measures, and market preferences for non-opioid therapies.

---

References

[1] U.S. Food and Drug Administration. (2021). Opioid Analgesics.
[2] MarketWatch. (2022). Global Opioid Analgesics Market.
[3] Substance Abuse and Mental Health Services Administration. (2022). Pain Treatment Trends.